Acute Drug-Induced Hepatic Injury

  • James H. Lewis


The field of hepatotoxicity owes much to the contributions of Dr. Hyman J. Zimmerman. The publication of his monograph, Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver in 1978 was eagerly awaited. Affectionately known as the Bible of hepatotoxicity, it represented nearly three decades of study and observations on every clinical and experimental aspect of drug-induced hepatic injury. Virtually all classes of medicinal agents and a multitude of chemicals and environmental toxins are capable of causing acute injury to the liver. The spectrum of hepatic lesions produced by these drugs and chemicals is diverse, mimicking most infectious, inflammatory, vascular, and neoplastic disorders. While a discussion of the hepatotoxicity of each agent is beyond the scope of this chapter, I nevertheless endeavor to provide an overview of various aspects of acute drug-induced liver disease. For information on particular agents, the reader is urged to consult Dr. Zimmerman’s textbook1 or any number of reference works.2–4


Valproic Acid Hepatic Injury Contraceptive Steroid Acetaminophen Overdose Halothane Hepatitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Zimmerman HJ: Hepatotoxicity. The Adverse Effects of Drugs and Other Chemicals on the Liver. Appleton-Century-Crofts, New York, 1978.Google Scholar
  2. 2.
    Zimmerman HJ, Maddrey WC: Toxic and drug-induced hepatitis, in Schiff L, Schiff ER (eds): Diseases of the Liver, 6th ed. JB Lippincott, Philadelphia, 1987, pp. 591–668.Google Scholar
  3. 3.
    Zimmerman HJ, Ishak KG: Hepatic injury due to drugs and toxins, in MacSween RNM, Anthony PP, Scheuer PJ (eds): Pathology of the Liver. Churchill Livingstone, Edinburgh, 1979, pp. 335–386.Google Scholar
  4. 4.
    Stricker BHC, Spoelstra P: Drug-Induced Hepatic Injury. Elsevier, Amsterdam, 1985.Google Scholar
  5. 5.
    Wade HJ, Frazer ES: Toxipathic hepatitis due to Fowler’s solution: A case treated with dimercaprol. Lancet 1:269–271, 1953.PubMedGoogle Scholar
  6. 6.
    Défalque RJ: The first delayed chloroform poisoning. Anesth Analg 47:374–382, 1968.PubMedGoogle Scholar
  7. 7.
    Zimmerman HJ: Clinical and laboratory manifestations of hepatotoxicity. Ann NY Acad Sci 104:954–987, 1963.Google Scholar
  8. 8.
    Dujovne CA, Chan CH, Zimmerman HJ: Sulfonamide hepatic injury. Review of the literature and report of a case due to sulfamethoxazole. Engl J Med 277:785–788, 1967.Google Scholar
  9. 9.
    Favreau M, Tannenbaum H, Lough J: Hepatotoxicity associated with gold therapy. Ann Intern Med 87:717–719, 1977.PubMedGoogle Scholar
  10. 10.
    Zimmerman HJ, Lewis JH: Drug-induced cholestasis. Med Tox 2:112–160, 1987.Google Scholar
  11. 11.
    Selye H: On the toxicity of estrogens with special reference to diethylstilbestrol. Can Med Assoc J 41:48–49, 1939.PubMedGoogle Scholar
  12. 12.
    Hanger FM JR, Gutman AB: Post-arsphenamine jaundice. JAMA 115:263–271, 1940.Google Scholar
  13. 13.
    Bassan H, Kendler J, Harinasuta U, Zimmerman HJ: Effects of an anabolic steroid (Norbolethone) on the function of the isolated perfused rat liver. Biochem Pharmacol 20:1429–1435, 1971.Google Scholar
  14. 14.
    Gargill SL, Lesses MF: Toxic reactions to thiouracil. Report of cases with one fatality. JAMA 127:890–891, 1945.Google Scholar
  15. 15.
    Hopen G, Nesthuss I, Laerum OD: Fatal carbamazepine-associated hepatitis. Report of two cases. Acta Med Scand 210:333–335, 1981.PubMedGoogle Scholar
  16. 16.
    Simpson DG, Walker JH: Hypersensitivity to para-aminosalicylic acid. Am J Med 29:297–306, 1960.Google Scholar
  17. 17.
    Zetzel L, Kaplan H: Liver damage concurrent with iproniazid administration. Engl J Med 258:1209–1212, 1958.Google Scholar
  18. 18.
    Rosenblum LE, Korn RJ, Zimmerman HJ: Hepatocellular jaundice as a complication of iproniazid therapy. Arch Intern Med 105:583–593, 1960.PubMedGoogle Scholar
  19. 19.
    Benjamin SB, Ishak KG, Zimmerman HJ, Grushka A: Phenylbutazone liver injury: A clinical-pathologic survey of 23 cases and review of the literature. Hepatology 1:255–263, 1981.PubMedGoogle Scholar
  20. 20.
    Zimmerman HJ: Hepatotoxic effects of oncotherapeutic agents. Prog Liver Dis 8:621–642, 1986.PubMedGoogle Scholar
  21. 21.
    Abernathy CO, Lukacs L, Zimmerman HJ: Toxicity of tricyclic antidepressants to isolated rat hepatocytes. Biochem Pharmacol 24:347–350, 1975.PubMedGoogle Scholar
  22. 22.
    Zimmerman HJ, Lewis JH: Hepatic toxicity of antimicrobial agents, in Root RK, Sande MA (eds): New Dimensions in Antimicrobial Therapy. Churchill Livingstone, New York, 1984, pp. 153–202.Google Scholar
  23. 23.
    Goldstein LI, Ishak KG: Hepatic injury associated with penicillin therapy. Arch Pathol Lab Med 98:114–117, 1974.Google Scholar
  24. 24.
    Johnson DA, Cattau EL Jr, Kuritsky JN, Zimmerman HJ: Liver involvement in the sulfone syndrome. Arch Intern Med 148:875–877, 1986.Google Scholar
  25. 25.
    Black M, Mitchell JR, Zimmerman HJ, et al: Isoniazid-associated hepatitis in 114 patients. Gastroenterology 69:289–302, 1975.PubMedGoogle Scholar
  26. 26.
    Mitchell JR, Zimmerman HJ, Ishak KG, et al: Isoniazid liver injury; clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med 84:181–192, 1976.PubMedGoogle Scholar
  27. 27.
    Benjamin SB, Goodman ZD, Ishak KS, et al: The morphologic spectrum of halothane-induced hepatic injury: Analysis of 77 cases. Hepatology 5:1163–1171, 1985.PubMedGoogle Scholar
  28. 28.
    Zimmerman HJ, Kendler J, Libber S: Studies on the in vitro cytotoxicity of erythromycin estolate. Sroc Soc Exp Biol Med 144:759–761, 1973.Google Scholar
  29. 29.
    Sharp JR, Ishak KG, Zimmerman HJ: Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin. Ann Intern Med 92:14–19, 1980.PubMedGoogle Scholar
  30. 30.
    Brown G, Zoidis J, Spring M: Hepatic damage during chlorpropamide therapy. JAMA 170:2085–2088, 1959.Google Scholar
  31. 31.
    Powers BJ, Cattau EL Jr, Zimmerman HJ: Chlorzoxazone hepatotoxic reactions. An analysis of 21 identified or presumed cases. Arch Intern Med 146:1183–1186, 1986.PubMedGoogle Scholar
  32. 32.
    Ishak KG: Hepatic lesions caused by anabolic and contraceptive steroids. Semin Liver Dis 1:116–128, 1981.PubMedGoogle Scholar
  33. 33.
    Lewis JH, Tice HL, Zimmerman HJ: Budd-Chiari syndrome associated with oral contraceptive steroids. Review of treatment of 47 cases. Dig Dis Sci 28:673–683, 1983.PubMedGoogle Scholar
  34. 34.
    Rodman JS, Deutch DJ, Gutman SI. Methyldopa hepatitis: A report of six cases and review of the literature. Am J Med 60:941–948, 1976.PubMedGoogle Scholar
  35. 35.
    Abemathy CO, Lukacs L, Zimmerman HJ: Adverse effects of chlorpromazine metabolites on isolated hepatocytes. Sroc Soc Exp Biol Med 155:474–478, 1977.Google Scholar
  36. 36.
    Kendler J, Bowry S, Seeff LB, Zimmerman HJ: Effect of chlorpromazine on the function of the perfused isolated liver. Biochem Pharmacol 20:2439–2445, 1971.PubMedGoogle Scholar
  37. 37.
    Ticktin HE, Zimmerman HJ: Hepatic dysfunction and jaundice in patients receiving triacetylolean-domycin. S Engl J Med 267:964–968, 1962.Google Scholar
  38. 38.
    Mihas AA, Holley P, Koff RS, Hirschowitz BI: Fulminant hepatitis and lymphocyte sensitization due to propylthiouricil. Gastroenterology 70:770–774, 1976.PubMedGoogle Scholar
  39. 39.
    Rotmensch HH, Yust I, Siegman-Igra Y, et al: Granulomatous hepatitis: A hypersensitivity response to procainamide. Ann Intern Med 89:646–647, 1978.PubMedGoogle Scholar
  40. 40.
    Zimmerman HJ: Papaverine revisited as a hepatotoxin. S Engl J Med 281:1364–1365, 1969.Google Scholar
  41. 41.
    Conn HO, Binder HJ, Orr HD: Ethionamide-induced hepatitis. A review with a report of an additional case. Am Rev Respir Dis 90:542–552, 1964.PubMedGoogle Scholar
  42. 42.
    Harinasuta U, Zimmerman HJ: Diphenylhydantoin sodium hepatitis. JAMA 203:1015–1018, 1968.Google Scholar
  43. 43.
    Reynolds TB, Peters RL, Yamada S: Chronic active and lupoid hepatitis caused by a laxative, oxy-phenisatin. S Engl J Med 285:813–820, 1971.Google Scholar
  44. 44.
    Zimmerman HJ: Aspirin-induced hepatic injury. Ann Intern Med 80:74–76, 1974.Google Scholar
  45. 45.
    Joshi PH, Conn HO: The syndrome of methoxyflurane-associated hepatitis. Ann Intern Med 80:395–401, 1974.PubMedGoogle Scholar
  46. 46.
    Zimmerman HJ: Effects of aspirin and acetaminophen on the liver. Arch Intern Med 141(3 spec no): 333–342, 1981.PubMedGoogle Scholar
  47. 47.
    Seeff LB, Boccherini BA, Zimmerman HJ, et al: Acetaminophen hepatotoxicity in alcoholics. A therapeutic misadventure. Ann Intern Med 104:399–404, 1986.PubMedGoogle Scholar
  48. 48.
    Lewis JH: Hepatic effects of drugs used in the treatment of peptic ulcer disease. Am J Gastroenterol 82:987–1003, 1987.PubMedGoogle Scholar
  49. 49.
    Zimmerman HJ; Ishak KG: Valproate-induced hepatic injury: Analyses of 23 fatal cases. Hepatology 2:591–597, 1982.PubMedGoogle Scholar
  50. 50.
    Lewis JH, Zimmerman HJ, Ishak KS, Mullick FG: Enflurane hepatotoxicity. A clinicopathologic study of 24 cases. Ann Intern Med 98:984–992, 1983.PubMedGoogle Scholar
  51. 51.
    Al-Ka was FH, Seeff LB, Berendson RA, et al: Allopurinol hepatotoxicity. Report of two cases and review of the literature. Ann Intern Med 95:588–590, 1981.Google Scholar
  52. 52.
    Pessary RED, Bichara M, Feldmann G, et al: Perhexaline maleate-induced cirrhosis. Gastroenterology 76:170–177, 1979.Google Scholar
  53. 53.
    Bruckstein AH, Attia AA: Oxacillin hepatitis. Two patients with liver biopsy and review of the literature. Am J Med 64:519–522, 1978.PubMedGoogle Scholar
  54. 54.
    Sotolongo RP, Neefe LI, Rudzki C, Ishak KG: Hypersensitivity reaction to sulfazalazine with severe hepatotoxicity. Gastroenterology 75:95–99, 1978.PubMedGoogle Scholar
  55. 55.
    Utili R, Boitnott JK, Zimmerman HJ: Dantrolene-associated hepatic injury. Incidence and character. Gastroenterology 72:810–816, 1977.Google Scholar
  56. 56.
    Abernathy CO, Utili R, Zimmerman HJ, Ezekiel M: The effects of dantrolene sodium on excretory function in the isolated perfused rat liver. Toxicol Appl Pharmacol 44:441–453, 1978.PubMedGoogle Scholar
  57. 57.
    Pearson K, Zimmerman HJ: Danazol and liver damage. Lancet 1:845–846, 1980.Google Scholar
  58. 58.
    Klein NC, Magida MG: Propoxyphene (Darvon) hepatotoxicity. Am J Dig Dis 16:467–469, 1971.PubMedGoogle Scholar
  59. 59.
    Lewis JH: Hepatoxicity of non-steroidal anti-inflammatory drugs. Clin Pharm 3:128–138, 1984.PubMedGoogle Scholar
  60. 60.
    Wood LJ, Mundo F, Searl J, Powell LW: Sulindac hepatotoxicity: Effects of acute and chronic exposure. Aust NZ J Med 15:397–401, 1985.Google Scholar
  61. 61.
    Scheuer P, Summerfield JA, Lal S, Sherlock S: Rifampicin hepatitis: A clinical histological study. Lancet 1:421–425, 1974.PubMedGoogle Scholar
  62. 62.
    Langan MN, Thomas P: Penicillamine-induced liver disease. Am J Gastroenterol 82:130–131, 1987.Google Scholar
  63. 63.
    Knoblauch M, Cueni B, Spycher M, et al: Dehydralazin-induzurte, akute Hepatitis bei IgM-Mangel. Schweiz Med Wochenschr 107:651–656, 1977.PubMedGoogle Scholar
  64. 64.
    Itoh S. Yamaba Y, Ichinoe A, Tsukuda Y: Hydralazine-induced liver injury. Dig Dis Sci 25:884–887, 1980.PubMedGoogle Scholar
  65. 65.
    Fang SS, Ginsberg AL, Dobbins WO III: Cholestatic jaundice associated with flurazepam hydrochloride. Ann Intern Med 89:363–364, 1978.PubMedGoogle Scholar
  66. 66.
    Mullick FG, Ishak KG, Mahabier R, et al: Hepatic injury associated with paraquat toxicity in humans. Liver 1:209–221, 1981.PubMedGoogle Scholar
  67. 67.
    Zimmerman HJ, Jacob L, Bassan H, et al: Effects of H2-blocking agents on hepatocytes in vitro; correlation with potential for causing hepatic disease in patients. Proc Soc Exp Biol Med 182:511–514, 1986.PubMedGoogle Scholar
  68. 68.
    Rahmat J, Gelfand RL, Gelfand MC, et al: Captopril-associated cholestatic jaundice. Ann Intern Med 102:56–58, 1985.PubMedGoogle Scholar
  69. 69.
    Poucell S, Ireton J, Valencia-Mayoral P, et al: Amiodarone-associated phospholipidosis and fibrosis of the liver. Light, immunohistochemical, an electron microscopic studies. Gastroenterology 86:926–936, 1984.PubMedGoogle Scholar
  70. 70.
    Zimmerman HJ, Abernathy CO, Lukacs L, Ezekiel M: Effects of ticrynasfen on hepatic excretory function in the isolated perfused rat liver. Hepatology 2:255–257, 1982.PubMedGoogle Scholar
  71. 71.
    Zimmerman HJ, Lewis JH, Ishak KG, Maddrey WC: Ticrynafen-associated hepatic injury. Analysis of 340 cases. Hepatology 4:315–323, 1984.PubMedGoogle Scholar
  72. 72.
    Lewis JH, Zimmerman HJ, Benson GD, Ishak KG: Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases. Gastroenterology 86:503–513, 1984.PubMedGoogle Scholar
  73. 73.
    Cohen DJ, Loertscher R, Rubin MF, et al: Cyclosporine: A new immunosuppressive agent for organ transplantation. Ann Intern Med 101:667–682, 1984.PubMedGoogle Scholar
  74. 74.
    Zimmerman HJ. Chenodeoxycholic acid and the liver: good news-bad news. (Editorial.) Hepatology 2:288–289, 1982.PubMedGoogle Scholar
  75. 75.
    Lovastatin for hypercholesterolemia. Med Lett 29:99-101, 1987.Google Scholar
  76. 76.
    Richter WO, Schwandt S: Serious side effect of nifedipine. Arch Intern Med 147:1852, 1987.PubMedGoogle Scholar
  77. 77.
    Adler E, Benjamin SB, Zimmerman HJ: Cholestatic hepatic injury related to warfarin exposure. Arch Intern Med 145:1837–1839, 1986.Google Scholar
  78. 78.
    Brodsky SJ, Cutler SS, Weiner DA, Klein MD: Hepatotoxicity due to treatment with verapamil. Ann Intern Med 94:490–491, 1981.PubMedGoogle Scholar
  79. 79.
    Simpson BR, Strunin L, Walton B: The halothane dilemma: A case for the defense. Br Med J 9:96–100, 1971.Google Scholar
  80. 80.
    Eger EI II, Smuckler EA, Ferrell LD, et al: Is enflurane hepatoxicS Anesth Anaig 65:21–30, 1986.Google Scholar
  81. 81.
    Humphries TJ, Myerson RM, Gifford LM, et al: A unique postmarket out-patient surveillance program of Cimetidine: report on phase II and final summary. Am J Gastroenterol 79:593–596, 1984.PubMedGoogle Scholar
  82. 82.
    Rossi AC, Knapp DE, Anello C, et al: Discovery of adverse drug reactions: A comparison of selective phase IV studies with spontaneous reporting methods. JAMA 249:2226–2228, 1983.PubMedGoogle Scholar
  83. 83.
    Faich GA, Knapp D, Dreis M, Turner W: National. Adverse Drug Reaction Surveillance: 1985. JAMA 257:2068–2070, 1987.PubMedGoogle Scholar
  84. 84.
    Dossing M, Buch Andreasen P: Drug-induced liver disease in Denmark. An analysis of 572 cases of hepatoxicity reported to the Danish Board of Adverse Reactions to Drugs. Scand J Gastroenterol 17:205–211, 1982.PubMedGoogle Scholar
  85. 85.
    Koff RS, Gardner R, Harinasuta U, et al: Profile of hyperbilirubinemia in three hospital populations. Clin Res. 18:680, 1970.Google Scholar
  86. 86.
    Miller RR: Hospital admissions due to adverse drug reactions. A report from the Boston Collaborative Drug Surveillance Program. Arch Intern Med 134:219–223, 1974.PubMedGoogle Scholar
  87. 87.
    Eastwood HOH: Causes of jaundice in the elderly: A survey of diagnosis and investigation. Geront Clin 13:69, 1971.Google Scholar
  88. 88.
    Graham GS: Chlorpromazine jaundice in a general hospital. Br Med J 2:1080, 1957.PubMedGoogle Scholar
  89. 89.
    Shimano S: Drug-induced hepatic injury with special reference to antitubercular agents. Acta Hepatol Jpn 6(suppl 74), 1965.Google Scholar
  90. 90.
    Trey C, Davidson CS: The management of fulminant hepatic failure, in Hopper H, Schaffner F (eds): Progress in Liver Disease, Vol. 3. Grune & Stratton, Orlando, Florida, 1970, pp. 282.Google Scholar
  91. 91.
    Caravati CM, Hooker TH: Acute massive hepatic necrosis with fatal hepatic failure. Am J Dig Dis 16:803, 1971.PubMedGoogle Scholar
  92. 92.
    Rakela J, Lang SM, Ludwig J, Baldus WP: Fulminant hepatitis: Mayo Clinic experience with 34 cases. Mayo Clin Proc 60:289–292, 1985.PubMedGoogle Scholar
  93. 93.
    Williams R, Gimson AES: An assessment of orthotopic liver transplantation in acute liver failure. Hepatology 4(suppl):22S–24S, 1984.PubMedGoogle Scholar
  94. 94.
    Bottiger LE, Furhoff AK, Holmberg L: Fatal reactions to drugs. A 10-year material from the Swedish Adverse Drug Reaction Committee. Acta Med Scand 205:451–456, 1979.PubMedGoogle Scholar
  95. 95.
    Koff RS, Fitts JJ, Sabesin SM, Zimmerman HJ: D-galactosamine hepatotoxicity. II. Mechanism of fatty liver production. Proc Soc Exp Biol Med 138:89–92, 1971.PubMedGoogle Scholar
  96. 96.
    Lullmann H, Lullmann-Rauch R, Wassermann O: Drug-induced phospholipidoses. CRC C rit Rev Toxicol 4:185–218, 1975.Google Scholar
  97. 97.
    Simon JB, Manley PN, Brien JF, Armstrong PW: Amiodarone hepatotoxicity simulating alcoholic liver disease. N Engl J Med 311:167–172, 1984.PubMedGoogle Scholar
  98. 98.
    Ranard RC, Lewis JH, Ragsdale BD, et al: Amiodarone hepatotoxicity: Histopathologic correlations. Gastroenterology 92:1766, 1987.Google Scholar
  99. 99.
    Zimmerman HJ: Drug-induced liver disease. Drugs 16:25–45, 1978.PubMedGoogle Scholar
  100. 100.
    Mitchell JR, Thorgeirsson UP, Black M, et al: Increased incidence of isoniazid hepatitis in rapid acetalators: Possible relation to hydrazine metabolites. Clin Pharmacol Ther 18:70–79, 1975.PubMedGoogle Scholar
  101. 101.
    Jacqz E, Hall SD, Branch RA: Genetically determined polymorphisms in drug oxidation. Hepatology 6:1020–1032, 1986.PubMedGoogle Scholar
  102. 102.
    Morgan NY, Reshef R, Shah RR, et al: Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut 25:1057–1064, 1984.PubMedGoogle Scholar
  103. 103.
    Hoft RH, Bunker JP, Goodman HI, Gregory PB: Halothane hepatitis in three pairs of closely related women. S Engl J Med 304:123–124, 1981.Google Scholar
  104. 104.
    Farrell G, Prendergast D, Murray M: Halothane hepatitis. Detection of a constitutional susceptibility factor. S Engl J Med 313:1310–1314, 1985.Google Scholar
  105. 105.
    Welch KI, Batchelor JR: HLA and drug reactions, in David M, Tredger JN, Williams R (eds): Drug Reactions and the Liver. Pittman Medical, London, 1981, pp. 111–117.Google Scholar
  106. 106.
    Hatoff DE, Cohen M, Schweigen BF, Talbert WM: Nitrofurantoin: Another cause of drug-induced chronic active hepatitisS Am J Med 67:117–121, 1979.PubMedGoogle Scholar
  107. 107.
    Gran JT, Husby G, Thorsby E: HLA DR antigens and gold toxicity. Ann Rheum Dis 42:63–66, 1983.PubMedGoogle Scholar
  108. 108.
    Zimmerman HJ: Effects of alcohol on other hepatotoxins. Alcoholism. Clin Exp Res 10:3–15, 1986.Google Scholar
  109. 109.
    Aw TY, Hanna P, Petrini J, Kaplowitz S: Hepatic drug metabolism and drug-induced liver injury, in Gitnick G (ed): Current Hepatology, Vol. 5. Year Book, Chicago, 1985, pp. 113–196.Google Scholar
  110. 110.
    Kaplowitz N, Aw TY, Simon FR, Stolz A: Drug-induced hepatotoxicity. Ann Intern Med 104:826–839, 1986.PubMedGoogle Scholar
  111. 111.
    Tribble DL, Aw TY, Jones DP: The pathophysiological significance of lipid peroxidation in oxidative cell injury. Hepatology 7:377–387, 1987.PubMedGoogle Scholar
  112. 112.
    Davis M, Vergani D, Eddleston ALWF, Williams R: Halothane hepatitis-toxicity and immunity, in Eddleston ALWF, Weber JCP, Williams R (eds): Immune Reactions in Liver Disease. Pitman Medical, London, 1979, pp. 235–296.Google Scholar
  113. 113.
    Dienstag JL: Halothane hepatitis. Allergy or idiosyncracyS S Engl J Med 303:102–104, 1980.Google Scholar
  114. 114.
    Vergani D, Mieli-Vergani G, Alberti A, et al: Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. S Engl J Med 303:66–71, 1980.Google Scholar
  115. 115.
    Mizoguchi Y, Ohnishi F, Monna T, et al: Studies on intrahepatic cholestasis induced in the rat by culture supernatant of activated lymphocytes. Hepatogastroenterology 28:147–151, 1981.PubMedGoogle Scholar
  116. 116.
    Allan LG, Hussey AJ, Howie J, et al: Hepatic glutathione S-transferase release after halothane anaesthesia: Open randomised comparison with isoflurane. Lancet 1:771–774, 1987.PubMedGoogle Scholar
  117. 117.
    Walton B, Simpson BR, Stunin L, et al: Unexplained hepatitis following halothane. Br Med J 1:1171–1176, 1976.PubMedGoogle Scholar
  118. 118.
    Caruso AC, Ranard RC, Lewis JH, et al: Multi-organ toxicity associated with amiodarone-induced hepatic dysfunction. Gastroenterology 92:1724, 1987.Google Scholar
  119. 119.
    American Thoracic Society: Treatment of tuberculosis and tuberculosis infection in adults and children. Am Rev Respir Dis 134:355–363, 1986.Google Scholar
  120. 120.
    Physicians Desk Reference, 41st ed. Medical Economics, Oradell, New Jersey, 1987.Google Scholar
  121. 121.
    Harinasuta U, Chomet B, Ishak K, Zimmerman HJ: Steatonecrosis—Mallory body type. Medicine (Baltimore) 46(2):141–162, 1967.Google Scholar
  122. 122.
    Cohen JA, Kaplan MM: The SGOT/SGPT ratio—An indicator of alcoholic liver disease. Dig Dis Sci 24:835–838, 1979.PubMedGoogle Scholar
  123. 123.
    Lewis JH, Schiff S. Methotrexate-induced chronic liver injury: guidelines for detection and prevention. Am J Gastroenterol 83(12), 1988.Google Scholar
  124. 124.
    Kaplowitz S. Drug-induced hepatotoxicity, in Gitnick G (ed): Current Hepatology, Vol. 6. Year Book, Chicago, 1986, pp. 239–268.Google Scholar
  125. 125.
    Speeg KV Jr, Patwardhan RV, Avant Gr, et al: Inhibition of microsomal drug metabolism by histamine H2-receptor antagonists studied in vivo and in vitro in rodents. Gastroenterology 82:84–88, 1982.Google Scholar
  126. 126.
    Vendemiale G, Altomare E, Trizio T, et al: Effect of acute and chronic Cimetidine administration on acetaminophen metabolism in humans. Am J Gastroenterol 82:131–134, 1987.Google Scholar
  127. 127.
    Jack, D, Thomas M, Skidmore IF: Ranitidine and paracetamol metabolism. Lancet 2:1067, 1985.PubMedGoogle Scholar
  128. 128.
    Speeg KV, Mitchell MC, Maldonado AL: Additive protection of Cimetidine and N-acetylcystaime treatment against acetaminophen-induced hepatic necrosis in the rat. J Pharmacol Exp Ther 234:550–554, 1985.PubMedGoogle Scholar
  129. 129.
    Burk RF: Hepatocytoprotective substances. Gastroenterology 81:397–398, 1981.PubMedGoogle Scholar
  130. 130.
    Orrego H, Kalant K, Israel Y, et al: Effect of short-term therapy with propylthiouracil in patients with alcoholic liver disease. Gastroenterology 76:105–115, 1979.PubMedGoogle Scholar
  131. 131.
    Orrego H, Blake JE, Blendis LM, et al: Long-term treatment of alcoholic liver disease with propylthiouracil. S Engl J Med 317:1421–1427, 1987.Google Scholar
  132. 132.
    Lewis JH, Zimmerman HJ, Garrett CT, Marcus JA: Threonine protects against hepatic injury due to valproic acid in rats. Gastroenterology 88:1675, 1985.Google Scholar

Copyright information

© Plenum Publishing Corporation 1989

Authors and Affiliations

  • James H. Lewis
    • 1
    • 2
  1. 1.Georgetown University School of MedicineUSA
  2. 2.Division of GastroenterologyGeorgetown University HospitalUSA

Personalised recommendations